Abstract
Currently, lung cancer is the leading cause of cancer-related death in western nations. Risk factors are usually associated with tobacco consumption, occupational exposure, radon and passive smoking. To date, many factors influence NSCLC behavior and, therefore, clinical response to therapeutic targets, such as epidermal growth factor (EGF) and its receptor (EGFR) and vascular endothelial growth factor (VEGF) and its receptor (VEGFR). Angiogenesis-related genetic polymorphisms are of primary interest in NSCLC research. Angiogenesis genetic polymorphisms, such as VEGF − 2578 C/A and VEGF − 1154 G/A, were correlated in previous studies with increased tumor VEGF expression, vascular density and poor survival. However, anti-angiogenic drugs did not show to be cost-effectiveness in NSCLC. This topic will address research involving angiogenesis genetic polymorphisms and NSCLC behavior.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- EGF:
-
Epidermal growth factor
- EGFR:
-
EGF receptor
- EGFR:
-
Epidermal growth factor receptor
- GWAS:
-
Genome-wide associate study
- HBO:
-
Hyperbaric oxygen
- HIF:
-
Hypoxia inducible factor
- KDR receptor:
-
Kinase insert domain receptor
- mTOR:
-
Mammalian target of rapamycin
- NSCLC:
-
Non-small cell lung cancer
- OS:
-
Overall survival
- PFS:
-
Progression free survival
- PIK3:
-
Phosphoinositide 3-kinase
- PlGF:
-
Placental growth factor
- SNP:
-
Single nucleotide polymorphism
- SOS:
-
Guanine nucleotide exchange factor sos
- TKI:
-
Tyrosine kinase inhibitor
- VEGF:
-
Vascular endothelial growth factor
- VEGFR:
-
VEGF receptor
References
Alberg A, Brock M, Samet J (2005) Epidemiology of lung cancer: looking to the future. J Clin Oncol 23(14):3175–3185
Lopez A, Collishaw N, Piha T (1994) A descriptive model of the cigarette epidemic in developed countries. Tob Control 3(3):242–247
Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, Whitehead M, Spaans JN, Graham BC, Goss GD (2008) Age and comorbidity as independent prognostic factors in the treatment of non–small-cell lung cancer: a review of National Cancer Institute of Canada clinical trials group trials. J Clin Oncol 26(1):54–59
Brundage M, Davies D, Mackillop W (2002) Prognostic factors in non-small cell lung cancer. Chest 122(3):1037–1057
de Mello RA, Marques DS, Medeiros R, Araújo AM (2011) Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. World J Clin Oncol 2(11):367–376
Futamura Y, Sawa T, Hasegawa T, Horiba A, Ishiguro T, Yoshida T, Iida T, Marui T, Murakami E, Azuma K et al (2011) Stereotactic radiotherapy following chemo-radiotherapy for lymph node metastasis of stage III non-small-cell lung cancer. Gan to Kagaku Ryoho 38(12):2191–2193
Hanagiri T, Sugio K, Mizukami M, Ichiki Y, Sugaya M, Yasuda M, Takenoyama M, Yasumoto K (2008) Significance of smoking as a postoperative prognostic factor in patients with non-small cell lung cancer. J Thorac Oncol 3(10):1127–1132
Rotunno M, Yu K, Lubin JH, Consonni D, Pesatori AC, Goldstein AM, Goldin LR, Wacholder S, Welch R, Burdette L et al (2009) Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mRNA expression. PLoS One 4(5):e5652
Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, Short S, Hlatky L, Vajkoczy P, Huber P, Folkman J (2009) Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 69(3):836
Balasubramanian S, Brown N, Reed M (2002) Role of genetic polymorphisms in tumour angiogenesis. Br J Cancer 87(10):1057–1065
Bonnesen B, Pappot H, Holmstav J, Skov BG (2009) Vascular endothelial growth factor a and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis. Lung Cancer 66(3):314–318
Araujo A, Ribeiro R, Azevedo I, Coelho A, Soares M, Sousa B, Pinto D, Lopes C, Medeiros R, Scagliotti G (2007) Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature. Oncologist 12(2):201–210
Zhu C, da Cunha SG, Ding K, Sakurada A, Cutz J, Liu N, Zhang T, Marrano P, Whitehead M, Squire J (2008) Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol 26(26):4268–4275
Selvaggi G, Novello S, Torri V, Leonardo E, De Giuli P, Borasio P, Mossetti C, Ardissone F, Lausi P, Scagliotti G (2004) Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 15(1):28–32
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388
Shepherd F, Rodrigues Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123–132
Zhou C, Wu Y, Chen G, Feng J, Liu X, Wang C, Zhang S, Wang J, Zhou S, Ren S et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancer Oncol 12(8):735–742
Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957
Herbst RS, Fukuoka M, Baselga J (2004) Gefitinib—a novel targeted approach to treating cancer. Nat Rev Cancer 4(12):979–987
de Mello RA, Costa BM, Reis RM, Hespanhol V (2012) Insights into angiogenesis in non-small cell lung cancer: molecular mechanisms, polymorphic genes, and targeted therapies. Recent Pat Anticancer Drug Discov 7(1):118–131
Schneider B, Wang M, Radovich M, Sledge G, Badve S, Thor A, Flockhart D, Hancock B, Davidson N, Gralow J (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26(28):4672–4678
Sheppard PM (1955) Genetic variability and polymorphism: synthesis. Cold Spring Harb Symp Quant Biol 20:271–275
Hsu TC, Klatt O (1958) Mammalian chromosomes in vitro. IX. On genetic polymorphism in cell populations. J Natl Cancer Inst 21(3):437–473
El-Khoueiry A, Lenz H (2011) Pharmacogenomics. In: DeVita VT, Lawrence TS, Rosenberg SA (eds) CANCER: principles and practice of oncology, 9th edn. Lippincott Williams & Wilkins, Philadelphia
Marques Santos DS (2012) “Papel prognóstico e preditivo do polimorfismo da IL-8-251 T/A no carcinoma epitelial do ovário”. Master degree. Porto: Instituto de Ciências Biomédicas Abel Salazar, University of Porto
Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S, Mullikin JC, Mortimore BJ, Willey DL (2001) A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409(6822):928–933
Harris AL (2002) Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2(1):38–47
Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT (2009) Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med 9(4):442–458
Crabtree H, Cramer W (1933) The action of radium on cancer cells. II.--some factors determining the susceptibility of cancer cells to radium. Proc R Soc Lond B 113(782):238–250
Schwarz G (1909) Über Desensibilisierung gegen Röntgen- und Radiumstrahlen. Münchener Medizinische Wochenschrift 24:1–2
Chan DA, Giaccia AJ (2007) Hypoxia, gene expression, and metastasis. Cancer Metastasis rev 26(2):333–339
Kim J, Gao P, Dang CV (2007) Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev 26(2):291–298
Varlotto J, Stevenson MA (2005) Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 63(1):25–36
Boogaerts M, Mittelman M, Vaupel P (2005) Beyond anaemia management: evolving role of erythropoietin therapy in neurological disorders, multiple myeloma and tumour hypoxia models. Oncology 69(2):22–30
Gray L, Conger A, Ebert M, Hornsey S, Scott O (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26(312):638–648
Mayer R, Hamilton-Farrell MR, van der Kleij AJ, Schmutz J, Granström G, Sicko Z, Melamed Y, Carl UM, Hartmann KA, Jansen EC (2005) Hyperbaric oxygen and radiotherapy. Strahlenther Onkol 181(2):113–123
Feldmeier J, Carl U, Hartmann K, Sminia P (2003) Hyperbaric oxygen: does it promote growth or recurrence of malignancy? Undersea Hyperb Med 30(1):1–18
Bennett M, Feldmeier J, Smee R, Milross C (2005) Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database Syst Rev 4:CD005007
Overgaard J, Horsman MR (1996) Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6(1):10–21
Overgaard J (2007) Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25(26):4066–4074
Kaanders JHAM, Bussink J, van der Kogel AJ (2002) ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 3(12):728–737
Jordan BF, Sonveaux P (2012) Targeting tumor perfusion and oxygenation to improve the outcome of anticancer therapy. Front Pharmacol 3:94
Rewari AN, Haffty BG, Wilson LD, Son YH, Joe JK, Ross DA, Papac RJ, Sasaki CT, Fischer JJ (2006) Postoperative concurrent chemoradiotherapy with mitomycin in advanced squamous cell carcinoma of the head and neck: results from three prospective randomized trials. Cancer J 12(2):123–129
Roberts KB, Urdaneta N, Vera R, Vera A, Gutierrez E, Aguilar Y, Ott S, Medina I, Sempere P, Rockwell S (2000) Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix. Int J Cancer 90(4):206–223
Bennewith KL, Dedhar S (2011) Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer 11:504
Albertella MR, Loadman PM, Jones PH, Phillips RM, Rampling R, Burnet N, Alcock C, Anthoney A, Vjaters E, Dunk CR (2008) Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res 14(4):1096–1104
Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, Wilson WR (2010) A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol 65(4):791–801
Chen CH, Lai JM, Chou TY, Chen CY, Su LJ, Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J et al (2009) VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PLoS One 4(4):e5052
Choong N, Salgia R, Vokes E (2008) Key signaling pathways and targets in lung cancer therapy. Clin Lung Cancer 8(suppl 2):52–60
Kerbel R (2008) Tumor angiogenesis. N Engl J Med 358(19):2039–2049
González RP, Leyva A, Melo RAB, Moreira RDM, Pessoa C, Farias RF, Moraes MO (2000) Método para estudo in vivo da angiogênese: indução de neovascularização na córnea de coelho. Acta Cir Bras 15(3):168–173
An SJ, Huang YS, Chen ZH, Su J, Yang Y, Chen JG, Yan HH, Lin QX, Yang JJ, Yang XN et al (2012) Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy. Med Oncol 29(2):627–632
Bremnes R, Camps C, Sirera R (2006) Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51(2):143–158
Dvorak H (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20(21):4368–4380
Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, Chen P, Das S, Jassem J, Rzyman W (2011) Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res 17(16):5257–5267
Dowlati A, Gray R, Sandler A, Schiller J, Johnson D (2008) Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non–small cell lung cancer treated with chemotherapy with or without bevacizumab—an eastern cooperative oncology group study. Clin Cancer Res 14(5):1407–1412
Duda D, Jain R, Willett C (2007) Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 25(26):4033–4042
Folkman J (2008) Tumor angiogenesis: from bench to bedside. In: Marmé D, Fusenig N (eds) Tumor angiogenesis: basic concepts and cancer therapy, 8th edn. Springer, Berlin, pp 3–28
Folkman J, Watson K, Ingber D, Hanahan D (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339(6219):58–61
Guan X, Yin M, Wei Q, Zhao H, Liu Z, Wang LE, Yuan X, O'Reilly M, Komaki R, Liao Z (2010) Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer 10(1):431
Dong Q, Feng J, Huang J, Bao G, Sha H, Gu W (2002) Vascular endothelial growth factor promotes hematogenous metastasis of cancer cells in patients with non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 24(2):142–146
Forgacs E, Zöchbauer-Müller S, Oláh E, Minna J (2001) Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol Oncol Res 7(1):6–13
Gessner C, Rechner B, Hammerschmidt S, Kuhn H, Hoheisel G, Sack U, Ruschpler P, Wirtz H (2009) Angiogenic markers in breath condensate identify non-small cell lung cancer. Lung Cancer 68:177
Hong TT, Zhang RX, Wu XH, Hua D (2012) Polymorphism of vascular endothelial growth factor− 1154G>A (rs1570360) with cancer risk: a meta-analysis of 16 case–control studies. Mol Biol Rep 39(5):5283–5289
Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer A, Strange R, Hutchinson P, Osborne J, Lear J, Smith A et al (2002) Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359(9304):397–401
Araújo A, Costa B, Pinto-Correia A, Fragoso M, Ferreira P, Dinis-Ribeiro M, Costa S, Reis R, Medeiros R (2011) Association between EGF +61A/G polymorphism and gastric cancer in Caucasians. World J Gastroenterol 17(4):488–492
Zhang Y, Cao C, Liang K (2010) Genetic polymorphism of epidermal growth factor 61A>G and cancer risk: a meta-analysis. Cancer Epidemiol 34(2):150–156
Costa B, Ferreira P, Costa S, Canedo P, Oliveira P, Silva A, Pardal F, Suriano G, Machado J, Lopes J et al (2007) Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res 13(9):2621–2626
Bhowmick D, Zhuang Z, Wait S, Weil R (2004) A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res 64(4):1220–1223
Wu G, Hasenberg T, Magdeburg R, Bönninghoff R, Sturm J, Keese M (2009) Association between EGF, TGF-beta1, VEGF gene polymorphism and colorectal cancer. World J Surg 33(1):124–129
Kang H, Choi J, Lee W, Kam S, Cha S, Kim C, Jung T (2007) Park J: +61A>G polymorphism in the EGF gene does not increase the risk of lung cancer. Respirology 12(6):902–905
Lim Y, Kim J, Song J, Hong M, Jin S, Yoon S, Park H, Choe B, Lee J, Yim S et al (2005) Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population. Neurosci Lett 374(3):157–160
de Mello RA, Ferreira M, Costa S, Costa BM, Pires FS, Neves I, Almeida MI, Cunha J, Oliveira P, Hespanhol V et al (2012) Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case-control study. Tumour Biol 33:1341. PMID:22457050
Weiss WA, Burns MJ, Hackett C, Aldape K, Hill JR, Kuriyama H, Kuriyama N, Milshteyn N, Roberts T, Wendland MF (2003) Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res 63(7):1589–1595
Brandt R, Eisenbrandt R, Leenders F, Zschiesche W, Binas B, Juergensen C, Theuring F (2000) Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation. Oncogene 19(17):2129–2137
Araújo A, Coelho A, de Mello RA, Azevedo I, Soares M, Queiroga H, Teixeira E, Parente B, Barata F (2012) Personalizing medicine - strategies for implementing the evaluation of ALK rearrangement in non-small-cell lung cancer in Portugal. Rev Port Pneumol 18:244. http://dx.doi.org/10.1016/j.rppneu.2012.04.011
Dong J, Dai J, Shu Y, Pan S, Xu L, Chen W, Wang Y, Jin G, Ma H, Zhang M (2010) Polymorphisms in EGFR and VEGF contribute to non-small cell lung cancer survival in a Chinese population. Carcinogenesis 31(6):1080–1086
Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, Rotunno M, Mirabello L, Jacobs K, Wheeler W, Yeager M (2009) A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet 85(5):679–691
Ito H, MacKay JD, Hosono S, Hida T, Yatabe Y, Mitsudomi T, Brennan P, Tanaka H, Matsuo K (2012) Association between a genome-wide association study-identified locus and the risk of lung cancer in Japanese population. J Thorac Oncol 7(5):790–798
Bae EY, Lee SY, Kang BK, Lee EJ, Choi YY, Kang HG, Choi JE, Jeon HS, Lee WK, Kam S (2012) Replication of results of genome-wide association studies on lung cancer susceptibility loci in a Korean population. Respirology 17(4):699–706
Li Y, Sheu C, Ye Y, de Andrade M, Wang L, Chang S, Aubry M, Aakre J, Allen M, Chen F et al (2010) Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol 11(4):321–330
Taylor J, Tyekucheva S, King DC, Hardison RC, Miller W, Chiaromonte F (2006) ESPERR: learning strong and weak signals in genomic sequence alignments to identify functional elements. Genome Res 16:1596–1604
Feldser DM, Hackett JA, Greider CW (2003) Telomere dysfunction and the initiation of genome instability. Nat Rev Cancer 3:623–627
Fernandez-Garcia I, Ortiz-de-Solorzano C, Montuenga LM (2008) Telomeres and telomerase in lung cancer. J Thorac Oncol 3:1085–1088
Lantuejoul S, Soria J, Moro-Sibilot D, Morat L, Veyrenc S, Lorimier P, Brichon P, Sabatier L, Brambilla C, Brambilla E (2004) Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br J Cancer 90(6):1222–1229
Aviel-Ronen S, Coe BP, Lau SK, da Cunha SG, Zhu CQ, Strumpf D, Jurisica I, Lam WL, Tsao MS (2008) Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. Proc Natl Acad Sci U S A 105(29):10155–10160
Wang Y, Broderick P, Webb E, Wu X, Vijayakrishnan J, Matakidou A, Qureshi M, Dong Q, Gu X, Chen WV (2008) Common 5p15. 33 and 6p21. 33 variants influence lung cancer risk. Nat Genet 40(12):1407–1409
Vincenti V, Cassano C, Rocchi M, Persico MG (1996) Assignment of the vascular endothelial growth factor gene to human chromosome 6p21. 3. Circulation 93(8):1493–1495
Naik NA, Bhat IA, Afroze D, Rasool R, Mir H, Andrabi SI, Shah S, Siddiqi MA, Shah ZA (2012) Vascular endothelial growth factor a gene (VEGFA) polymorphisms and expression of VEGFA gene in lung cancer patients of Kashmir Valley (India). Tumour Biol 33(3):833–839
Stevens A, Soden J, Brenchley P, Ralph S, Ray D (2003) Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63(4):812–816
Vaziri S, Kim J, Ganapathi M, Ganapathi R (2010) Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. Curr Oncol Rep 12(2):102–108
Zhai R, Liu G, Zhou W, Su L, Heist R, Lynch T, Wain J, Asomaning K, Lin X, Christiani D (2008) Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non–small cell lung cancer. Clin Cancer Res 14(2):612–617
Toschi L, Cappuzzo F (2007) Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 12(2):211–220
Harris R, Chung E, Coffey R (2003) EGF receptor ligands. Exp Cell Res 284(1):2–13
Shepherd FA, Rosell R (2007) Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. J Thorac Oncol 2(Suppl 2):S68–S76
Sculier J, Chansky K, Crowley J, Van Meerbeeck J, Goldstraw P (2008) The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant Tumors and the proposals for the 7th edition. J Thorac Oncol 3(5):457–466
Singhal S, Vachani A, Antin-Ozerkis D, Kaiser L, Albelda S (2005) Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non–small cell lung cancer: a review. Clin Cancer Res 11(11):3974–3986
Shen L, Ji H (2011) More on crizotinib. N Engl J med 364(8):777
Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U (2009) Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27(26):4247–4253
Schrump D, Giaccone G, Kelsey K, Marks L (2008) Non small cell lung cancer. In: DeVita V, Lawrence T, Rosenberg S, Weinberg R, DePinho R (eds) DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology, vol 1, 8th edn. Lippincott Williams & Wilkins, Philadelphia, pp 896–939
Pao W, Miller V, Politi K, Ricly G, Somwar R, Zakowski M, Kris M, Varmus H (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):225–235
Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH (2006) DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983–991
Masago K, Fujita S, Kim Y, Hatachi Y, Fukuhara A, Nagai H, Irisa K, Ichikawa M, Mio T, Mishima M (2009) Effect of vascular endothelial growth factor polymorphisms on survival in advanced stage non small cell lung cancer. Cancer Sci 100(10):1917–1922
Dajczman E, Kasymjanova G, Kreisman H, Swinton N, Pepe C, Small D (2008) Should patient-rated performance status affect treatment decisions in advanced lung cancer? J Thorac Oncol 3(10):1133–1136
Pérez-Soler R, Chachoua A, Hammond L, Rowinsky E, Huberman M, Karp D, Rigas J, Clark G, Santabárbara P, Bonomi P (2004) Determinants of tumor response and survival with erlotinib in patients with non—small-cell lung cancer. J Clin Oncol 22(16):3238–3247
Miller V, Riely G, Zakowski M, Li A, Patel J, Heelan R, Kris M, Sandler A, Carbone D, Tsao A (2008) Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 26(9):1472–1478
Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas G, Mazieres J, Whittom R, Ward C, Mayne K et al (2011) Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 29(31):4113–4120
Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, Venitz J, Figg WD (2009) The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 8(9):2496–2508
Zacharatos P, Kotsinas A, Tsantoulis P, Evangelou K, Kletsas D, Asimacopoulos PJ, Doussis-Anagnostopoulou I, Pezzella F, Gatter K, Papavassiliou AG et al (2001) Relationship of the K-ras/c-mos expression patterns with angiogenesis in non-small cell lung carcinomas. Mol Med 7(9):590–597
Heist RS, Zhai R, Liu G, Zhou W, Lin X, Su L, Asomaning K, Lynch TJ, Wain JC, Christiani DC (2008) VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 26(6):856–862
Bieniasz M, Oszajca K, Eusebio M, Kordiak J, Bartkowiak J, Szemraj J (2009) The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients. Lung Cancer 66(3):319–326
Lee SJ, Lee SY, Jeon HS, Park SH, Jang JS, Lee GY, Son JW, Kim CH, Lee WK, Kam S et al (2005) Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomark Prev 14(3):571–575
Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch A, Eroles P (2012) The single-nucleotide polymorphisms +936 C/T VEGF and −710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population. Breast Cancer Res Treat 133:769. PMID: 22315135
Koukourakis M, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Siviridis E (2004) VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46(3):293–298
Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J (2011) Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non–small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res 71(16):5512–5521
Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27(8):1227–1234
Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ (2012) Lung cancer in never smokers–a review. Eur J Cancer 48(9):1299–1311
Li Y, Sun Z, Cunningham JM, Aubry MC, Wampfler JA, Croghan GA, Johnson C, Wu D, Aakre JA, Molina J (2011) Genetic variations in multiple drug action pathways and survival in advanced stage non–small cell lung cancer treated with chemotherapy. Clin Cancer Res 17(11):3830–3840
Ma F, Xu B, Lin D, Sun T, Shi Y (2011) Effect of rs2293347 polymorphism in EGFR on the clinical efficacy of gefitinib in patients with non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 14(8):642–645
Nie Q, Yang X, An S, Zhang X, Yang J, Zhong W, Liao R, Chen Z, Su J, Xie Z (2011) CYP1A1* 2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA) n polymorphism. Eur J Cancer 47(13):1962–1970
Dy G, Adjei A (2009) Emerging therapeutic targets in non-small cell lung cancer. Proc am Thorac Soc 6(2):218–223
Competing Interest
The authors declare that they do not have any competing interests.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
De Mello, R.A., Luis, M., Araújo, A., Reis, R.M., Hespanhol, V. (2017). The Role of Angiogenesis in Non-small Cell Lung Cancer Tumor Behavior. In: Mehta, J., Mathur, P., Dhalla, N. (eds) Biochemical Basis and Therapeutic Implications of Angiogenesis. Advances in Biochemistry in Health and Disease, vol 6. Springer, Cham. https://doi.org/10.1007/978-3-319-61115-0_10
Download citation
DOI: https://doi.org/10.1007/978-3-319-61115-0_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-61114-3
Online ISBN: 978-3-319-61115-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)